ArticleDrug and alcohol review2026
Safe Supply at Insite, North America's First Supervised Consumption Site: A Case Report of Reduced Harms From the Toxic Drug Supply in a Client Prescribed Powdered Fentanyl Alternative.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasingly unpredictable and toxic unregulated drug supply puts people who use drugs at high risk of overdose and death. In April 2022, Insite-North America's first sanctioned supervised consumption site-started a prescribed powdered fentanyl safer supply program available to patients for on-site consumption. This novel pharmaceutical product, created in partnership with a community compounding pharmacy, can be smoked or injected; is free of dangerous contaminants (e.g., xylazine and non-prescribed benzodiazepines); and has a predictable concentration. This case describes a man in his 50s with no fixed address and severe opioid use disorder and stimulant use disorder prescribed powdered fentanyl at Insite, which led to reduced use of unregulated drugs, increased supervised consumption site engagement and increased retention on oral opioid agonist therapy. Expansion of supervised consumption services to incorporate the provision of prescribed alternatives to the drug supply for on-site supervised consumption holds promise and should be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.